New data and the hard pomeron

New structure-function data are in excellent agreement with the existence of a hard pomeron, with intercept about 1.4. It gives a very economical description of the data. Having fixed 2 parameters from the data for the real-photon cross section $\sigma^{\gamma p}$, we need just 5 further parameters to fit the data for $F_2(x,Q^2)$ with $x\leq 0.001$. The available data range from $Q^2=0.045$ to 35 GeV$^2$. With guesses consistent with dimensional counting for the $x$ dependences of our three separate terms, the fit extends well to larger $x$ and to $Q^2=5000$ GeV$^2$. With no additional parameters, it gives a good description of data for the charm structure function $F_2^c(x,Q^2)$ from $Q^2=0$ to 130 GeV$^2$. The two pomerons also give a good description of both the $W$ and the $t$ dependence of $\gamma p\to J/\psi p$.Comment: 11 pages, plain tex, with 10 figures embedded using epsf. (Spurious figure removed.

Searching for non-Gaussianity in the VSA data

We have tested Very Small Array (VSA) observations of three regions of sky for the presence of non-Gaussianity, using high-order cumulants, Minkowski functionals, a wavelet-based test and a Bayesian joint power spectrum/non-Gaussianity analysis. We find the data from two regions to be consistent with Gaussianity. In the third region, we obtain a 96.7% detection of non-Gaussianity using the wavelet test. We perform simulations to characterise the tests, and conclude that this is consistent with expected residual point source contamination. There is therefore no evidence that this detection is of cosmological origin. Our simulations show that the tests would be sensitive to any residual point sources above the data's source subtraction level of 20 mJy. The tests are also sensitive to cosmic string networks at an rms fluctuation level of $105 \mu K$ (i.e. equivalent to the best-fit observed value). They are not sensitive to string-induced fluctuations if an equal rms of Gaussian CDM fluctuations is added, thereby reducing the fluctuations due to the strings network to $74 \mu K$ rms . We especially highlight the usefulness of non-Gaussianity testing in eliminating systematic effects from our data.Comment: Minor corrections; accepted for publication to MNRA

Estimating the bispectrum of the Very Small Array data

We estimate the bispectrum of the Very Small Array data from the compact and extended configuration observations released in December 2002, and compare our results to those obtained from Gaussian simulations. There is a slight excess of large bispectrum values for two individual fields, but this does not appear when the fields are combined. Given our expected level of residual point sources, we do not expect these to be the source of the discrepancy. Using the compact configuration data, we put an upper limit of 5400 on the value of f_NL, the non-linear coupling parameter, at 95 per cent confidence. We test our bispectrum estimator using non-Gaussian simulations with a known bispectrum, and recover the input values.Comment: 17 pages, 16 figures, replaced with version accepted by MNRAS. Primordial bispectrum recalculated and figure 11 change

IR Divergences in Inflation and Entropy Perturbations

We study leading order perturbative corrections to the two point correlation function of the scalar field describing the curvature perturbation in a slow-roll inflationary background, paying particular attention to the contribution of entropy mode loops. We find that the infrared divergences are worse than in pure de Sitter space: they are power law rather than logarithmic. The validity of perturbation theory and thus of the effective field theory of cosmological perturbations leads to stringent constraints on the coupling constants describing the interactions, in our model the quartic self-interaction coupling constant of the entropy field. If the self coupling constant is larger than some critical value which depends in particular on the duration of the inflationary phase, then perturbation theory breaks down. Our analysis may have implications for the stability of de Sitter space: the quantum effects which lead to an instability of de Sitter space will be larger in magnitude in the presence of entropy fluctuations.Comment: 28 pages, minor changes in Sec 3.3, reference adde

The Clustering of Galaxies in SDSS-III DR9 Baryon Oscillation Spectroscopic Survey: Constraints on Primordial Non-Gaussianity

We analyze the density field of 264,283 galaxies observed by the Sloan Digital Sky Survey (SDSS)-III Baryon Oscillation Spectroscopic Survey (BOSS) and included in the SDSS data release nine (DR9). In total, the SDSS DR9 BOSS data includes spectroscopic redshifts for over 400,000 galaxies spread over a footprint of more than 3,000 deg^2. We measure the power spectrum of these galaxies with redshifts 0.43 < z < 0.7 in order to constrain the amount of local non-Gaussianity, f_NL,local, in the primordial density field, paying particular attention to the impact of systematic uncertainties. The BOSS galaxy density field is systematically affected by the local stellar density and this influences the ability to accurately measure f_NL,local. In the absence of any correction, we find (erroneously) that the probability that f_NL,local is greater than zero, P(f_NL,local >0), is 99.5%. After quantifying and correcting for the systematic bias and including the added uncertainty, we find -45 < f_NL,local 0) = 91.0%. A more conservative approach assumes that we have only learned the k-dependence of the systematic bias and allows any amplitude for the systematic correction; we find that the systematic effect is not fully degenerate with that of f_NL,local, and we determine that -82 < f_NL,local < 178 (at 95% confidence) and P(f_NL,local >0) = 68%. This analysis demonstrates the importance of accounting for the impact of Galactic foregrounds on f_NL,local measurements. We outline the methods that account for these systematic biases and uncertainties. We expect our methods to yield robust constraints on f_NL,local for both our own and future large-scale-structure investigations.Comment: Matches version to be published in MNRAS. While in press, we found an error that caused all of our fNL values to be off by a factor of h^2. Our conclusions (and nearly 100% of the text) are unchanged because they were all in reference to the probability of fNL > 0 and the relative effect of systematics on the recovered constraint

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Effects of Triclosan-Containing Rinse on the Dynamics and Antimicrobial Susceptibility of In Vitro Plaque Ecosystems

Dental plaque microcosms were established under a feast-famine regimen within constant-depth film fermentors and exposed four times daily postfeeding to a triclosan (TR)-containing rinse (dentifrice) (TRD). This was diluted so that the antimicrobial content was 0.6 mg/ml. Microcosms were characterized by heterotrophic plate counts and PCR-denaturing gradient gel electrophoresis (DGGE) with primers specific for the V2-V3 region of the eubacterial 16S rRNA gene (rDNA). Dominant isolates and PCR amplicons were identified by partial sequencing of 16S rDNA. TRD caused considerable decreases in the counts of both gram-negative organisms and total anaerobic cells, transiently lowered the numbers of streptococci and actinomycetes, and markedly increased the proportion of lactobacilli. DGGE indicated the presence of putatively unculturable bacteria and showed that a Porphyromonas sp. and Selenomonas infelix had been inhibited by TRD. Pure culture studies of 10 oral bacteria (eight genera) showed that Neisseria subflava, Prevotella nigrescens, and Porphyromonas gingivalis were highly susceptible to TR, while the lactobacilli and streptococci were the least susceptible. Clonal expansion of the lactobacilli in the pulsed microcosm could be explained on the basis of TR activity. The mean MICs of TR, chlorhexidine, erythromycin, penicillin V, and vancomycin for the population before and after 5 days of exposure to TRD showed few significant changes. In conclusion, changes in plaque microcosm populations following repeated exposure to TRD showed inhibition of the most susceptible flora and clonal expansion of less susceptible species

Effects of a Chlorhexidine Gluconate-Containing Mouthwash on the Vitality and Antimicrobial Susceptibility of In Vitro Oral Bacterial Ecosystems

Oral bacterial microcosms, established using saliva inocula from three individuals, were maintained under a feast-famine regime within constant-depth film fermenters. Steady-state communities were exposed four times daily, postfeeding, to a chlorhexidine (CHX) gluconate-containing mouthwash (CHXM) diluted to 0.06% (wt/vol) antimicrobial content. The microcosms were characterized by heterotrophic plate counts and PCR-denaturing gradient gel electrophoresis (DGGE). CHXM caused significant decreases in both total anaerobe and total aerobe/facultative anaerobe counts (P < 0.05), together with lesser decreases in gram-negative anaerobes. The degree of streptococcal and actinomycete inhibition varied considerably among individuals. DGGE showed that CHXM exposure caused considerable decreases in microbial diversity, including marked reductions in Prevotella sp. and Selenomonas infelix. Pure-culture studies of 10 oral bacteria (eight genera) showed that Actinomyces naeslundii, Veillonella dispar, Prevotella nigrescens, and the streptococci were highly susceptible to CHX, while Lactobacillus rhamnosus, Fusobacterium nucleatum, and Neisseria subflava were the least susceptible. Determination of the MICs of triclosan, CHX, erythromycin, penicillin V, vancomycin, and metronidazole for microcosm isolates, before and after 5 days of CHXM exposure, showed that CHXM exposure altered the distribution of isolates toward those that were less susceptible to CHX (P < 0.05). Changes in susceptibility distributions for the other test agents were not statistically significant. In conclusion, population changes in plaque microcosms following repeated exposure to CHXM represented an inhibition of the most susceptible flora with a clonal expansion of less susceptible species